They Just Don't Get...
Health Care: Drugs
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$3.03 -0.07 | -2.26%
02/09/12 - 04:00 PM ET
935.15K / 1.73M
Vol / Avg. Vol:3.13 / 3.10
Open / Prev. Close:3.01 - 3.18
Today's Range:1.77 - 4.80
52 Wk Range:51.22%
Performance YTD:TheStreet Rating:
Portfolios with AVNR
- Portfolio NameUser Type
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
- Contributor5 Stocks With the Largest S...
- Usergm401
- Userparvardigar
- UserBioTech
Latest AVNR Headlines from TheStreet
- AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript 02.07.12 | 10:02 pm
- Friday's Top 10 Articles, Videos on TheStreet 01.20.12 | 02:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- AVANIR Stock Hits New 52-Week Low (AVNR) 12.14.11 | 03:12 pm
- Avanir's CEO Discusses Q4 2011 Results - Earnings Call Transcript 12.12.11 | 11:12 pm
- Biotech Stock Mailbag: 2011 Report Card 11.25.11 | 05:11 am
- AVANIR Stock Hits New 52-Week Low (AVNR) 11.21.11 | 10:11 am
- 10 Most Shorted Stocks in Biotech 10.04.11 | 09:10 am
- 5 Stocks Under $10 Setting Up to Trade Higher 09.15.11 | 01:09 pm
- Biotech Stock Mailbag: Cyclacel Pharma 08.12.11 | 05:08 am
Press Releases for AVNR
- Avanir Pharmaceuticals Announces Publication Of Phase III Study Results Showing Efficacy And Safety Of AVP-923 In The Treatment Of Diabetic Neuropathic Pain - PR Newswire 02.08.12 | 09:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 First Quarter Financial Results And Conference Call - PR Newswire 01.30.12 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2011 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.06.11 | 08:12 am
- Avanir Pharmaceuticals To Participate In Piper Jaffray Health Care Conference - PR Newswire 11.22.11 | 08:11 am
- Avanir Pharmaceuticals Announces EMA Acceptance Of Marketing Authorization Application For NUEDEXTA - PR Newswire 11.17.11 | 08:11 am
- Avanir Pharmaceuticals Announces Enrollment Of First Patient In PRIME Study Of AVP-923 In Central Neuropathic Pain In Multiple Sclerosis - PR Newswire 11.03.11 | 08:11 am
- Avanir Pharmaceuticals Submits European Marketing Authorization Application For NUEDEXTA - PR Newswire 10.31.11 | 08:10 am
- Avanir Pharmaceuticals To Present Data At MS-Focused ECTRIMS Annual Meeting - PR Newswire 10.18.11 | 08:10 am
- Avanir Pharmaceuticals To Present Data At The 2011 American Congress Of Rehabilitation Medicine/American Society For Neurorehabilitation Medicine Annual Conference - PR Newswire 10.12.11 | 04:10 pm
- Avanir Pharmaceuticals To Participate In Two Investor Conferences - PR Newswire 09.15.11 | 04:09 pm
Partner Headlines for AVNR
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
- Avanir - Closing Short Position - Seeking Alpha 11.27.11 | 08:11 am
- 10 Small-Cap Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 10:11 pm
- Avanir Pain Drug Should Provide Long-Term Growth - Seeking Alpha 09.30.11 | 06:09 pm
- Avanir: Congressional Inquiry Into the Pricing of Nuedexta Abandoned - Seeking Alpha 07.22.11 | 09:07 am
- Hearing Negative Chatter in Avanir Pharmaceuticals - Benzinga 06.30.11 | 01:06 pm
- Jefferies' Upadates - Benzinga 06.03.11 | 09:06 am
- Investors Should Take Notice of Congressional Questions Regarding Nuedexta Pricing - Seeking Alpha 05.27.11 | 09:05 am
- 9 Healthcare Companies Expecting May Catalysts - Seeking Alpha 05.04.11 | 08:05 am
- Friday Options Recap - Seeking Alpha 04.29.11 | 04:04 pm
